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Abstract
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) is potentially a very important therapeutic as it shows
selectivity for inducing apoptosis in cancer cells whilst normal cells are refractory. TRAIL binding to its cognate receptors,
Death Receptors-4 and -5, leads to recruitment of caspase-8 and classical activation of downstream effector caspases, leading
to apoptosis. As with many drugs however, TRAIL’s usefulness is limited by resistance, either innate or acquired. We describe
here the development of a novel 384-well high-throughput screening (HTS) strategy for identifying potential TRAIL-sensitizing
agents that act solely in a caspase-8 dependent manner. By utilizing a TRAIL resistant cell line lacking caspase-8 (NB7)
compared to the same cells reconstituted with the wild-type protein, or with a catalytically inactive point mutant of caspase-8,
we are able to identify compounds that act specifically through the caspase-8 axis, rather than through general toxicity. In
addition, false positive hits can easily be ‘‘weeded out’’ in this assay due to their activity in cells lacking caspase-8-inducible
activity.Screeningofthelibraryofpharmacologicallyactivecompounds(LOPAC)wasperformedasbothproof-of-conceptand
to discover potential unknown TRAIL sensitizers whose mechanism is caspase-8 mediated. We identified known TRAIL
sensitizers from the library and identified new compounds that appear to sensitize specifically through caspase-8. In sum, we
demonstrate proof-of-concept and discovery of novel compounds with a screening strategy optimized for the detection of
caspase-8 pathway-specific TRAIL sensitizers. This screen was performed in the 384-well format, but could easily be further
miniaturized, allows easy identification of artifactual false positives, and is highly scalable to accommodate diverse libraries.
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Introduction
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand
(TRAIL) is of great potential use as an anti-cancer therapeutic,
however, its evaluation and use as a potential therapeutic agent
have been limited by resistance. TRAIL selectively induces
apoptosis in cancer cells whilst normal cells are refractory [1]. It
is safe when administered in vivo and shows none of the toxicity
usually associated with other members of the Tumor Necrosis
Factor (TNF)-superfamily [2]. TRAIL is a naturally occurring
cytokine that canonically acts by binding as a homotrimer to
Death Receptor (DR)-4 or -5, resulting in recruitment of adapter
molecules such as FADD and caspase-8. This recruitment and
clustering results in caspase-8 dimerization, activation, processing
and release from the complex. Activated caspase-8, in turn,
activates the effector caspases resulting in classical apoptotic cell
death [3]. DR4 and DR5 are widely expressed on cancer cells and
it has been suggested that this may be one reason for TRAIL’s
anti-tumor properties [4]. However, a full understanding of the
mechanisms of TRAIL selectivity remains elusive. TRAIL has also
been demonstrated to bind to two ‘‘decoy receptors’’, DcR1 and
DcR2. Both of these receptors lack intracellular domains capable
of transducing apoptosis and may also account for the selectivity
and/or resistance associated with TRAIL signaling.
As TRAIL resistance is a major preclusion to its clinical use, we
envisaged a novel high-throughput screen (HTS) to identify
sensitizing agents. As non-specificity and toxicity are a major
drawback with conventional chemotherapeutics, we proposed to
discover novel agents acting primarily through the caspase-8 axis
as opposed to generalized toxicity. Utilization of the caspase-8 null
neuroblastoma cell line, NB7, and the same line reconstituted with
either wild-type or a catalytically inactive point mutant of caspase-
8 (C360A) [5] in parallel allows the identification of chemical
agents that act specifically via the caspase-8 apoptotic pathway.
The use of all three cell lines in parallel will allow easy
identification of false positives that induce non-specific cell death.
Concomitantly, we investigated the ability of chemical com-
pounds to sensitize or potentiate caspase-8-induced cell death in
response to low concentrations of TRAIL. For proof-of-concept
analysis, the library of pharmacologically active compounds
(LOPAC) of 1280 compounds was chosen due to its relatively
small size and the fact that all agents have biological activity. We
propose that this pilot screen, using in parallel the three cell lines
discussed above, provides us with proof-of-concept for a larger
screening campaign to follow. Indeed, while the use of cells lacking
functional caspase-8 may seem redundant, they are included in the
primary screen here due to the ‘‘proof-of-concept’’ nature of the
initial screen and should allow for more rigorous identification of
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13375any anomalies. Larger and more relevant chemical libraries will be
screened only against cells with functional caspase-8 whilst the cells
lacking the enzyme will be utilized in the secondary confirmations.
We demonstrate development of a novel 384-well HTS that
allows simple identification of generally toxic ‘‘false positives’’.
Further, we have detected known TRAIL synergizers and
previously undescribed sensitizing agents. The system is semi-
automated and highly scalable so that vastly greater compound
numbers can easily be tested.
Results
Many cancer cells are resistant to TRAIL, yet the exact
mechanisms are unknown and probably vary widely (e.g. [6]).
Epigenetic silencing of caspase-8 has been reported for several
different cancer cells and caspase-8 re-expression can restore
TRAIL-mediated killing [7,8]. We show that the neuroblastoma
NB7 cells are deficient in caspase-8 (Fig. 1A, [9,10]) yet express
death receptors DR4 and DR5 and caspases -3 (an effector
caspase) and -10 (an apical caspase). Interestingly, these cells are
refractory to TRAIL-induced apoptosis even when caspase-8 is re-
expressed (Fig. 1B). The cells are, however, sensitive to apoptosis
induced by the serine-threonine kinase inhibitor staurosporine,
indicating that the underlying apoptotic effector machinery is
intact (Fig. 1C). We further note that staurosporine kills NB7 cells
in a caspase-8 independent manner. Thus, our cells are a suitable
model system for the identification of novel TRAIL-sensitizing
agents acting through the caspase-8 axis.
As proteosome inhibition has proven to be effective in the
treatment of certain cancers, we first investigated whether MG-
132 would sensitize NB7 cells re-expressing caspase-8
(NB7+Casp8 cells) to TRAIL-induced apoptosis. Pre-treatment
of the cells with 2 mM MG-132 for 4 hours prior to 20 hours of
treatment with TRAIL (e.g. Fig. 2A) results in apoptosis of
approximately 90% of the NB7+Casp8 cells (even with only
3.125 ng/mL TRAIL) while the cells deficient in caspase-8 remain
refractory (Fig. 2B). We further show that the same assay can be
applied to breast cancer cells expressing a silencing caspase-8
shRNA or a non-silencing scrambled control. The majority of the
cells are refractory to TRAIL even at high concentrations yet MG-
Figure 1. NB7 cells are TRAIL resistant yet possess intact apoptotic machinery. A) Immunoblot analysis of apoptotic protein expression in
NB7 cells. B) Cell survival assay (MTS) on NB7 cells treated with TRAIL as described (24 h). C) Cell survival assay (MTS) on NB7 cells treated with
staurosporine (24 h). All dose response curves provided were carried out in at least triplicate at least three independent times and a representative
graph is shown. Data values are averages +/2 S.E.M. We note the S.E.M. values for some samples are extremely small and therefore may be difficult to
see in the graph.
doi:10.1371/journal.pone.0013375.g001
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manner (Fig. 2C). The MDA-MB-231 breast cancer cells were
chosen as they have been shown to express TRAIL receptors and
to possess intact downstream apoptotic machinery [11]. Further-
more, these cells allow us to demonstrate functionality in another
cell type and to utilize shRNA as another method to ‘‘knock
down’’ the protein of interest. Thus our system and protocols
should be readily transferable to investigate other systems and
targets. The ease with which the assay could be successfully
miniaturized to 384-well format suggests automation and further
miniaturization to a 1536-well format should be possible, while
maintaining sensitivity and statistical rigor. This is extremely
important as the costs associated with screening large chemical
libraries are not inconsiderate.
For the screen itself, a luminescent read-out for cell viability
(CellTiter-GloH Luminescent Cell Viability Assay, Promega
Corp., Madison, WI) was chosen as the primary measure because
there is generally less spectral interference by test compounds
using luminescence than with absorbance-based viability assays. Z’
factors take into account the variability and dynamic range of the
assay signal across entire plates and are used to judge the statistical
significance of each individual well. In general, cellular assays with
Z’$0.4 are considered sufficiently rigorous for single measure-
ments. Our assay greatly exceeds this benchmark with Z’=0.73 –
Figure 2. MG-132 acts as TRAIL sensitizer in NB7 cells with caspase-8 re-constituted. A) Schematic of experimental time-line. B) Cell
survival assays (CellTiter-Glo) on NB7 and NB7+Casp8 cells pre-treated for 4 h with 2 mM MG-132 before treatment with TRAIL as described for
20 h (left panel) or the same cells treated with varying concentrations of MG-132 before addition of TRAIL (10 ng/mL) as above. Data values are
averages +/2 S.E.M. C) Cell survival assay of MDA-MB-231+Control shRNA and MDA-MD-231+Casp8 shRNA cells pretreated with either vehicle or
MG-132 (2 mM) before addition of TRAIL for 20 h. Data values are averages +/2 S.E.M. We note the S.E.M. values for some samples are extremely small
and therefore may be difficult to see in the graph. D) Work flow of hit rates, confirmations and retesting of compounds.
doi:10.1371/journal.pone.0013375.g002
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assessed for their ability to kill NB7+Casp8 cells more potently in
the presence of TRAIL. MG-132 was utilized as a positive control
in our system. The LOPAC library was screened at a
concentration of 5 mM against the three cell lines in the presence
of 10 ng/mL TRAIL. Compounds were considered potential
TRAIL sensitizers if viability in the NB7+Casp8 + TRAIL
condition was less than 50% of the vehicle-only control and at least
20% less than the viability of the NB7 + TRAIL and/or
NB7+Casp8C360A + TRAIL conditions. ‘‘Potent’’ compounds
were defined as those compounds that resulted in cell viability of
less than 15% as compared to the vehicle-only control under all
test conditions (wherein sensitization is masked due to high toxicity
at 5 mM). The library contained altogether 32 (2.5%) potential
caspase-8-dependent, TRAIL sensitizing agents, of which five
were termed as ‘‘potent’’ compounds due to observed killing of all
three cell lines, based on the criteria described above.
Of the potent compounds, four (Bay 11-7085, 4-aminopyridine,
DL-erythro-dihydrosphingosine, and b-lapachone) were retested
over a lower concentration range in the presence or absence of
TRAIL but none were confirmed as sensitizing agents in our
system. The fifth potent compound, DL-alpha-methyl-p-tyrosine,
was unavailable for purchase and was dropped from the
campaign.
A secondary screen of the remaining 27 potential caspase-8
specific hits was performed by testing the compounds at 5 mMi n
six conditions consisting of all three cell lines in the absence or
presence of TRAIL. This secondary screen served two purposes: a)
to confirm the primary screen results and b) to assay the extent, if
any, of TRAIL sensitization in the context of caspase-8 or the
catalytically inactive point mutant, where an attenuated, but
measurable, effect is seen with MG-132. This retesting confirmed
that seven compounds were true caspase-8 axis TRAIL sensitizers.
A comprehensive search of the literature revealed that five of the
compounds (camptothecin, genistein, paclitaxel, wortmannin, and
thapsigargin) had been previously reported as TRAIL synergizers
[12–16] and two (YC-1 and APDC) are previously unidentified
TRAIL-sensitizing compounds (Table 1). Compounds dropped
from the campaign at this point consisted of those that did not
reconfirm (11 compounds) and those that lacked significant
sensitization to TRAIL (cell viability in the presence of the
compound + TRAIL is greater than 80% of compound only-
treated cells; nine compounds). A work flow of hit rates,
confirmations and retesting of the compounds is shown in Fig. 2D.
Activity of YC-1 and APDC was re-analyzed by TRAIL dose-
response (Fig. 3A–D). As described previously, NB7 cells and those
reconstituted with the wild-type, or a catalytically inactive mutant
of caspase-8 were pretreated for 4 hours with APDC (1 mM), YC-1
(5 mM), MG-132 (1 mM) or the clinically-relevant proteosome
inhibitor Bortezomib (5 nM). Cells were then incubated with
TRAIL for 20 hours before cell viability was assessed via the
CellTiter-Glo assay. APDC, YC-1 and MG-132 were confirmed
as novel TRAIL sensitizing agents whilst the FDA-approved agent,
Bortezomib, demonstrated caspase-8-dependent TRAIL-sensitiza-
tion at 5 nM. Although the native CASP10 gene is intact and
caspase-10 protein is expressed in the NB7 cells (Fig. 1A), it does
not appear to be involved in this modulation of TRAIL-induced
apoptosis.
Phase contrast images of NB7+Casp8 cells treated with vehicle,
APDC, MG-132 or YC-1 before addition of TRAIL for 20 h as
before are shown in Fig. 4A. Cells treated with vehicle and TRAIL
as described appeared healthy while cells pretreated with the other
three agents followed by TRAIL treatment demonstrated a
condensed phenotype typical of a dying cell. These cells do not
appear to die via anoikis, as only little detachment takes place
(Fig. 4A), however the small number of detached cells are dead as
assessed by ethidium homodimer uptake. In addition to the loss of
cell viability measured by CellTiter-Glo, cell death can also be
detected in NB7+Casp8 cells after treatment with APDC followed
by TRAIL as described previously. APDC sensitization to TRAIL-
induced killing was assessed using LIVE/DEAD H Viability/
Cytotoxicity Kit (Molecular Probes) whereby green fluorescence
signifies live cells (Fig. 4B). We note that cells treated with vehicle
or TRAIL alone are healthy and cells treated with APDC alone
show only minor cell loss while maintaining the green fluorescence
associated with live cells. In turn, cells treated with APDC followed
by TRAIL results in a marked loss of cell number coupled with
reduced green ‘‘live cell’’ signal intensity. A few red fluorescing
(dying) cells are also observed, however it is of note that dead,
unattached cells will fail to produce red fluorescence, resulting in
less red signal observed.
To further investigate the putative role of the agents in
promoting caspase-8 activity, we assessed the ability of the agents
to sensitize the NB7+Casp8 cells to TRAIL-mediated LETD
peptide cleavage using the Caspase-Glo 8 assay system (Promega
Corp.). Cells were treated with APDC (1 mM), YC-1 (5 mM) or
vehicle control as described before addition of 20 ng/mL TRAIL
and a time course of caspase-8 activation is presented in Fig. 4C.
We also show by immunoblot analysis that TRAIL treatment
results in caspase-8 processing only when the cells are pre-treated
with APDC or YC-1, but not with vehicle alone (Fig. 4C). As such,
both agents demonstrate the ability to promote TRAIL-mediated
caspase-8 activation, suggesting that they likely act on upstream
molecules of the pathway. We also demonstrate that the small
peptide inhibitors of caspase-8 (zIETD-fmk) and the pan-caspase
inhibitor, zVAD-fmk, provide complete protection from the
TRAIL killing sensitized by APDC (1 mM), YC-1 (5 mM) and
MG-132 (1 mM) (Fig. 4D).
In sum, we describe here a cellular model of TRAIL resistance
that is retained even upon caspase-8 re-expression. We also show
the design and optimization of a 384-well high throughput assay
that is highly scalable. By screening the LOPAC library using this
assay, we identified five known and two previously undescribed
TRAIL-sensitizing agents that are confirmed with concentration-
dependent curves produced from cell viability measurements.
Discussion
Current cancer chemotherapeutics are significantly limited by a
lack of selectivity for the intended target and deleterious side
Table 1
Compound Reported Mechanism Viability*
Camptothecin Topo-I inhibitor 37.1%
Genistein Tyrosine kinase inhibitor 14.9%
Paclitaxel Microtubule disassembly inhibitor 43.9%
Wortmannin PI3-K inhibitor 39.0%
Thapsigargin SERCA inhibitor 20.1%
APDC mGluR II agonist 29.2%
YC-1 Guanylate cyclase activator 30.6%
*Viability is defined as % cell survival of NB7+Casp8 cells treated with drug
(5 mM) +20 ng/mL TRAIL as compared to cells treated with vehicle (data from
original screen).
doi:10.1371/journal.pone.0013375.t001
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antibodies offer greatly more selectivity, they are susceptible to
inherent or acquired resistance. Therefore targeted apoptosis is an
attractive methodology for removal of the supernumerary cells
associated with cancer progression. One potentially valuable agent
is TRAIL. As mentioned previously, TRAIL shows selectivity for
cancer cells, but resistance remains a problem. Resistance due to
up-regulation of the decoy receptors can be simply overcome by
using targeted agonistic antibodies. Indeed, antibodies that target
specific death receptors and have little-to-no affinity for the decoy
receptors may prove to be more potent and selective than TRAIL
itself. Even with highly specific agonistic antibody therapy
however, resistance may still occur due to intracellular alterations
in the apoptotic cascade. In keeping with a small molecule
pharmacological approach, we describe here a novel screening
strategy optimized for the detection of caspase-8 pathway-specific
Figure 3. Cell survival TRAIL dose response curves. Cell viability measurements (CellTiter-Glo) on NB7 cells treated with A) 1 mM APDC
(Ammonium pyrrolidinedithiocarbamate), B) 5 mM YC-1 [3-(59-Hydroxymethyl-29-furyl)-1-benzyl indazole], C) 1 mM MG-132 or D) 5 nM Bortezomib for
4 h and TRAIL for 20 h as described. Cell viability is normalized to that of compound alone (APDC, YC-1, MG-132 and Bortezomib, respectively).
E) Single agent toxicity (CellTiter-Glo) on NB7 cells treated with drug alone for 24 h. All dose-response curves were carried out in at least triplicatea t
least three independent times. A representative graph is shown. Data values are averages +/2 S.E.M.
doi:10.1371/journal.pone.0013375.g003
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concept screen.
Caspase-8 is an apical protease involved in the ‘‘extrinsic’’ or
death receptor-mediated form of cell death and, as such, would
seem to be an ideal candidate for silencing or deletion in cancers.
Surprisingly, however, the protein is rarely silenced or absent in
cancers, making it an extremely attractive therapeutic intervention
point [10]. By utilizing a cell system that lacks caspase-8 (NB7)
compared to cells with the functional protein re-expressed, we are
able to differentiate between sensitizing agents that act through the
caspase-8 pathway as opposed to agents acting through other
mechanisms. We show that while NB7 cells express DR4 and
DR5, they remain TRAIL resistant, even when functional caspase-
8 is re-expressed (Fig. 1B). This is likely due to alterations in the
intracellular apoptotic or survival pathway machinery. Indeed, the
FDA-approved proteosome inhibitor Bortezomib has been shown
to act in part by preventing IkB degradation, thereby blocking NF-
kB mediated cell survival. Similarly, we demonstrate that
proteasome inhibition with MG-132 or Bortezomib results in
TRAIL sensitization in a caspase-8 specific manner (Fig. 2 and 3).
Although NB7+Casp8 cells are resistant to TRAIL concentrations
up to 1 mg/mL (Fig. 1B), a 4 hour pre-treatment with 2 mM MG-
132 allows 90–95% killing with less than 10 ng/mL TRAIL
(Fig. 2). We note, however, that caspase-8 re-expression does not
result in differential sensitivity to the other non-specific apoptosis
inducers such as the serine threonine kinase inhibitor staurospor-
ine (Fig. 1C). Thus, our model system truly allows identification of
TRAIL-sensitizing agents acting selectively via the caspase-8
apoptotic axis, as re-expression of the protein alone has no effect
on generalized toxicity. The objective of our screen was to show
that compounds that sensitize cells to TRAIL-mediated death, and
whose mechanism involves caspase-8 in some way, could be
identified by screening the three neuroblastoma lines in parallel
and in the presence of TRAIL. To this end, we screened the 1280
compound LOPAC collection and indeed, all five known TRAIL
sensitizers identified from the screen (camptothecin, genistein,
paclitaxel, wortmannin, and thapsigargin) have known mecha-
nisms of action involving caspase-8 [12–16].The entirety of the
screen was performed in the presence of TRAIL for two reasons:
1) All three of the neuroblastoma lines used in the screen are
completely refractory to the levels of TRAIL used in the screen,
which is to say that the viability signal from ‘‘vehicle + TRAIL’’
wells did not significantly differ from that from ‘‘vehicle – TRAIL’’
and so could be used to define the high end of the dynamic range
of signal without running additional conditions in parallel, which
would add cost to the assay and 2) that, by definition, a ‘‘hit’’ in the
screen should be more potent in the presence of TRAIL, thereby
lowering the signal in the corresponding well on only the
NB7+Casp8 plate, thus increasing the sensitivity of the assay.
We are aware that the set-up of the primary screen utilized here
does not differentiate between compounds that act through the
caspase-8 axis and those that do so and also sensitize with TRAIL.
In the current work, we address this question in the secondary
assay where hits from the primary screen were tested in the
presence and absence of TRAIL; however, depending on the size
and content of the library, the condition of the NB7+Casp8 cells
with PBS instead of TRAIL can easily be added to the screen, or
run instead of the point mutant condition. In fact, we believe the
tailorability of this assay is an asset because a screen can be
performed to find compounds of specific action.
As TRAIL is a potentially important cancer therapeutic, many
laboratories have attempted to find sensitizing agents utilizing a
wide range of chemical libraries against various different cell types.
Similar studies by other investigators utilizing a renal cell
carcinoma model to search for TRAIL-sensitizing agents [17]
have also demonstrated that novel agents of this class can be
identified by such a strategy. These studies also confirmed MG-
132 as a TRAIL-sensitizing agent. Other strategies have involved
assessing the ability of known anti-cancer agents to act as TRAIL-
sensitizing agents. Treatment of TRAIL resistant hepatocellular
carcinoma cells with specific kinase inhibitors or known chemo-
therapeutic drugs revealed that both classes of agent could
sensitize to TRAIL in a caspase-dependent manner [18]. Another
study of the effects of known chemotherapeutic agents in two
established ovarian cancer cell lines, however, showed that
cisplatin and paclitaxel had no TRAIL-sensitizing abilities [19].
This investigation did however identify the flexible heteroarotinoid
compound SHetA2 as an extrinsic apoptosis sensitizing agent.
Thus the testing of potential TRAIL sensitizers against cells of
various tissue types or against cancer cell lines harboring genetic
deletions, mutations or amplifications of clinical significance may
aid clinicians in assessing if certain agents may prove more
effective in certain cancer types. The previously unidentified
sensitizers from our screen (Table 1) include APDC (ammonium
pyrrolidinedithiocarbamate) and YC-1 (3-(59-hydroxymethyl-29-
furyl)-1-benzyl indazole). APDC was originally described as a
selective group II mGluR agonist and YC-1 as a soluble guanylate
cyclase activator. At present time, it remains unknown whether
these roles are related to their TRAIL-sensitizing abilities.
Interestingly, YC-1 has also been reported to block HIF1a activity
[20] and therefore may also operate at a transcriptional level.
In sum, we demonstrate the development of a 384-well HTS
that allows identification of TRAIL-sensitizing agents acting
specifically through the caspase-8 apoptotic pathways. The assay
is highly automated, cost effective, amenable to multi-plexing
analysis such as fluorescence-based caspase activation, and allows
simple identification of false positive hits. We identified five known
sensitizing agents from the LOPAC library along with two
previously undescribed sensitizing agents. Future work will involve
screening of larger and more relevant chemical compound
libraries with a view to identifying lead compounds of potential
clinical significance. In addition, screening of the F.D.A.-approved
oncology drugs may provide insights into the clinical use of known
agents, such as Bortezomib, as potential TRAIL sensitizers.
Materials and Methods
Reagents
Unless otherwise specified, all reagents were from Sigma-
Aldrich (St. Louis, MO). Primocin was obtained from InvivoGen
(San Diego, CA), Bortezomib from LC Laboratories (Woburn,
MA), and MG-132 and TRAIL are from Calbiochem (La Jolla,
CA). Small peptide caspase inhibitors are from BD Biosciences (La
Jolla, CA).
Preparation of cellular protein extracts
Cells were treated as described for experimental conditions.
Media supernatants were removed by vacuum and the cells
washed in ice-cold PBS. The cells were scraped in 1 mL of ice-cold
PBS and pelleted by centrifugation at 20,000 g for 2 min at 4uC.
Pellets were then re-suspended in an appropriate volume of cell
lysis buffer containing 40 mM Tris (pH 8.0), 200 mM NaCl, 0.2%
Triton X-100, 10% glycerol, 2 mM b-glycerophosphate, 500 mM
NaF and a protease inhibitor cocktail (#1 697 498, Roche
Diagnostics, Mannheim, Germany) and incubated on ice for
10 min with occasional agitation. The suspension was clarified by
centrifugation at 20,000 g for 10 min at 4uC to yield supernatants
HTS for TRAIL Sensitizers
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determined using a modified method of Bradford [21].
Immunoblotting analysis
Protein extracts were resolved on SDS-polyacrylamide gels and
then electrophoretically transferred onto PVDF membranes
(Immobilon-P, Millipore, Temecula, CA) by standard methodol-
ogy. Membranes were blocked for 1 h in TBS-T (20 mM Tris-
HCl, pH 7.6, 150 mM NaCl, 0.05% Tween) containing 5% (w/v)
non-fat dried milk and were incubated rocking overnight at 4uC
with the appropriate primary antibody: anti-a-tubulin (DM1A,
1:4000) (Calbiochem, La Jolla, CA); anti-caspase-8 (C15, 1:500)
(kind gift from Dr. Marcus Peter, University of Chicago, Chicago,
IL); anti-caspase-10 (ab2012, 1:2000) (Novus Biologicals); anti-
caspase-3 (#610322, 1:2000) and anti-DR4 (#556544, 1:1000)
(both from BD Biosciences, La Jolla, CA) and anti-DR5 (#3696,
1:1000) (Cell Signaling Technology, Danvers, MA). After
incubation for 1 h with anti-rabbit IgG (111-035-003), or -mouse
IgG (115-035-003) secondary antibodies conjugated to horseradish
peroxidase (Jackson ImmunoResearch Laboratories Inc., West
Grove, PA), bands were visualized using enhanced chemilumines-
cence (SuperSignalH West Pico Chemiluminescent substrate,
#34080, Pierce, Rockford, IL).
Cell culture and HTS design
Caspase-8 deficient NB7 cells were a kind gift from Dr. Jill Lahti
(St. Jude Children’s Research Hospital, Memphis, TN) and were
maintained in RPMI 1640 supplemented with 10% (v/v) FBS, and
penicillin/streptomycin/L-Glutamine (Omega Scientific Inc, Tar-
zana, CA). Stable cell lines expressing caspase-8 or a proteolyt-
ically inactive protein are as described previously [10,22].
The initial screen of the LOPAC 1280 library (Sigma) was
performed in 384-well white, clear-bottom TC plates (Greiner Bio-
One, Monroe, NC) using luminescence as the primary read-out
for cellular viability as measured with the CellTiter-GloH
Luminescent Cell Viability Assay (Promega Corp., Madison,
Figure 4. TRAIL-sensitized cell death results in the morphological signs of apoptosis. A) Phase contrast images (10x magnification) of
NB7+Casp8 cells treated with vehicle, 1 mM APDC, 1 mM MG-132 or 5 mM YC-1 before addition of 20 ng/mL TRAIL for 20 h. B) LIVE/DEAD H Viability/
Cytotoxicity assay of cells treated with either vehicle, 1 mM APDC, 20 ng/mL TRAIL or both the APDC and TRAIL combined, whereby green
fluorescence signifies live and red fluorescence signifies dying cells. C) Caspase-Glo 8 assay time course of cells treated with vehicle, 1 mM APDC or
5 mM YC-1 before addition of 20 ng/mL TRAIL for the indicated time. Data values are averages +/2 S.E.M. Inset in C) Immunoblot of caspase-8
processing in NB7+Casp8 cells treated with vehicle, APDC (2 mM) or YC-1 (5 mM) for 4 h before addition of TRAIL (20 ng/mL) for 18 h. D) Cell viability
measurements (CellTiter-Glo) on NB7+Casp8 cells treated with 1 mM APDC, 5 mM YC-1, or 1 mM MG-132 in the presence and absence of the small
peptide caspase inhibitors, zIETD-fmk or zVAD-fmk (both 50 mM), for 4 h and TRAIL (20 ng/mL) for 20 h.
doi:10.1371/journal.pone.0013375.g004
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NB7+Casp8C360A lines were seeded at 750 cells/well in 50 mL
complete medium and allowed to attach overnight. Test
compounds were then added via an ECHO 550 acoustic pipettor
(Labcyte, Sunnyvale, CA) at 25 nL/well for a final compound
concentration of 5 mM and a final DMSO concentration of 0.03%
(v/v). The plates were incubated for 4 hours, at which time
TRAIL was added in PBS at 10 mL/well for a final concentration
of 10 ng/mL via a MultiDrop Combi (Thermo Fisher Scientific,
Waltham, MA). The plates were incubated an additional
20 hours, then CellTiterGlo reagent was added via MultiDrop
Combi at 25 mL/well. The plates were orbitally shaken for 15
minutes and the resulting luminescence recorded with an Envision
multimode plate reader (Perkin Elmer, Waltham, MA). Z’-factors
were independently calculated for each cell line using lumines-
cence from vehicle-treated cells as high signal and that from
vehicle-treated medium as the low signal [23].
Cell survival assays
MTS assays were carried out using Promega Corporation’s
(Madison, WI) CellTiter 96 AQueous Non-Radioactive Cell
Proliferation Assay exactly as per manufacturer’s instructions.
Briefly, cells are treated as described before addition of 1/5
volume of assay reagent. Cells are then incubated at 37uC for 1 h
before absorbance (490 nm) is read on a Biotek EL800 plate
reader (Biotek, Winooski, VT).
Hoechst and LIVE/DEAD staining
LIVE/DEADH Viability/Cytotoxicity Kit (Molecular Probes,
Eugene, OR) was used as per manufacturer’s instructions. Cells
were plated in 6-well dishes, and treated 24 hours later with 5 mM
MG-132 or APDC, as indicated in figure. Subsequently, four
hours later, 20 ng/ml TRAIL was added as appropriate.
Following a further 20 hour incubation, the cells were incubated
with live/dead stains (L-3224, Invitrogen, Carlsbad, CA).
Specifically, the cells were incubated with 1 mM Calcein-AM,
2 mM ethidium homodimer, and 100 nM Hoechst 33342 for 30
minutes at 37uC. Fluorescence was then imaged using confocal
microscopy.
Caspase-Glo 8 assay
The Caspase-Glo 8 Assay (Promega Corp., Madison, WI)
system was used as per manufacturer’s instructions. Briefly, cells
are treated as described before addition of 1/2 volume of assay
reagent. Lysates are then incubated at room temperature for 1 h
before luminescence is measured on a Biotek Synergy 2 plate
reader.
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